Anti Obesity Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data
Report Summary
Anti Obesity Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Anti Obesity Drugs industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Anti Obesity Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Anti Obesity Drugs worldwide and market share by regions, with company and product introduction, position in the Anti Obesity Drugs market
Market status and development trend of Anti Obesity Drugs by types and applications
Cost and profit status of Anti Obesity Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Anti Obesity Drugs market as:
Global Anti Obesity Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Anti Obesity Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Oral Medicine
Diet Patch
Diet Tea
Global Anti Obesity Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Men
Women
Global Anti Obesity Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Anti Obesity Drugs Sales Volume, Revenue, Price and Gross Margin):
Pfizer
Merck
Roche
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Novo Nordisk
Eisai
Norgine
Arena Pharmaceuticals
Orexigen Therapeutics
Vivus
Alizyme
Rhythm Pharmaceuticals
Shionogi
Zafgan
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
Anti Obesity Drugs-Global Market Status & Trend Report 2013-2023 Top 20 Countries Data offers a comprehensive analysis on Anti Obesity Drugs industry, standing on the readers? perspective, delivering detailed market data in Global major 20 countries and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provides useful data and information. Key questions answered by this report include:
Worldwide and Top 20 Countries Market Size of Anti Obesity Drugs 2013-2017, and development forecast 2018-2023
Main manufacturers/suppliers of Anti Obesity Drugs worldwide and market share by regions, with company and product introduction, position in the Anti Obesity Drugs market
Market status and development trend of Anti Obesity Drugs by types and applications
Cost and profit status of Anti Obesity Drugs, and marketing status
Market growth drivers and challenges
The report segments the global Anti Obesity Drugs market as:
Global Anti Obesity Drugs Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):
North America (United States, Canada and Mexico)
Europe (Germany, UK, France, Italy, Russia, Spain and Benelux)
Asia Pacific (China, Japan, India, Southeast Asia and Australia)
Latin America (Brazil, Argentina and Colombia)
Middle East and Africa
Global Anti Obesity Drugs Market: Type Segment Analysis (Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):
Oral Medicine
Diet Patch
Diet Tea
Global Anti Obesity Drugs Market: Application Segment Analysis (Consumption Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)
Men
Women
Global Anti Obesity Drugs Market: Manufacturers Segment Analysis (Company and Product introduction, Anti Obesity Drugs Sales Volume, Revenue, Price and Gross Margin):
Pfizer
Merck
Roche
GlaxoSmithKline
AstraZeneca
Boehringer Ingelheim
Novo Nordisk
Eisai
Norgine
Arena Pharmaceuticals
Orexigen Therapeutics
Vivus
Alizyme
Rhythm Pharmaceuticals
Shionogi
Zafgan
In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.
CHAPTER 1 OVERVIEW OF ANTI OBESITY DRUGS
1.1 Definition of Anti Obesity Drugs in This Report
1.2 Commercial Types of Anti Obesity Drugs
1.2.1 Oral Medicine
1.2.2 Diet Patch
1.2.3 Diet Tea
1.3 Downstream Application of Anti Obesity Drugs
1.3.1 Men
1.3.2 Women
1.4 Development History of Anti Obesity Drugs
1.5 Market Status and Trend of Anti Obesity Drugs 2013-2023
1.5.1 Global Anti Obesity Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti Obesity Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Anti Obesity Drugs 2013-2017
2.2 Sales Market of Anti Obesity Drugs by Regions
2.2.1 Sales Volume of Anti Obesity Drugs by Regions
2.2.2 Sales Value of Anti Obesity Drugs by Regions
2.3 Production Market of Anti Obesity Drugs by Regions
2.4 Global Market Forecast of Anti Obesity Drugs 2018-2023
2.4.1 Global Market Forecast of Anti Obesity Drugs 2018-2023
2.4.2 Market Forecast of Anti Obesity Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Anti Obesity Drugs by Types
3.2 Sales Value of Anti Obesity Drugs by Types
3.3 Market Forecast of Anti Obesity Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Anti Obesity Drugs by Downstream Industry
4.2 Global Market Forecast of Anti Obesity Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Anti Obesity Drugs Market Status by Countries
5.1.1 North America Anti Obesity Drugs Sales by Countries (2013-2017)
5.1.2 North America Anti Obesity Drugs Revenue by Countries (2013-2017)
5.1.3 United States Anti Obesity Drugs Market Status (2013-2017)
5.1.4 Canada Anti Obesity Drugs Market Status (2013-2017)
5.1.5 Mexico Anti Obesity Drugs Market Status (2013-2017)
5.2 North America Anti Obesity Drugs Market Status by Manufacturers
5.3 North America Anti Obesity Drugs Market Status by Type (2013-2017)
5.3.1 North America Anti Obesity Drugs Sales by Type (2013-2017)
5.3.2 North America Anti Obesity Drugs Revenue by Type (2013-2017)
5.4 North America Anti Obesity Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Anti Obesity Drugs Market Status by Countries
6.1.1 Europe Anti Obesity Drugs Sales by Countries (2013-2017)
6.1.2 Europe Anti Obesity Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Anti Obesity Drugs Market Status (2013-2017)
6.1.4 UK Anti Obesity Drugs Market Status (2013-2017)
6.1.5 France Anti Obesity Drugs Market Status (2013-2017)
6.1.6 Italy Anti Obesity Drugs Market Status (2013-2017)
6.1.7 Russia Anti Obesity Drugs Market Status (2013-2017)
6.1.8 Spain Anti Obesity Drugs Market Status (2013-2017)
6.1.9 Benelux Anti Obesity Drugs Market Status (2013-2017)
6.2 Europe Anti Obesity Drugs Market Status by Manufacturers
6.3 Europe Anti Obesity Drugs Market Status by Type (2013-2017)
6.3.1 Europe Anti Obesity Drugs Sales by Type (2013-2017)
6.3.2 Europe Anti Obesity Drugs Revenue by Type (2013-2017)
6.4 Europe Anti Obesity Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Anti Obesity Drugs Market Status by Countries
7.1.1 Asia Pacific Anti Obesity Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Anti Obesity Drugs Revenue by Countries (2013-2017)
7.1.3 China Anti Obesity Drugs Market Status (2013-2017)
7.1.4 Japan Anti Obesity Drugs Market Status (2013-2017)
7.1.5 India Anti Obesity Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Anti Obesity Drugs Market Status (2013-2017)
7.1.7 Australia Anti Obesity Drugs Market Status (2013-2017)
7.2 Asia Pacific Anti Obesity Drugs Market Status by Manufacturers
7.3 Asia Pacific Anti Obesity Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Anti Obesity Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Anti Obesity Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Anti Obesity Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Anti Obesity Drugs Market Status by Countries
8.1.1 Latin America Anti Obesity Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Anti Obesity Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Anti Obesity Drugs Market Status (2013-2017)
8.1.4 Argentina Anti Obesity Drugs Market Status (2013-2017)
8.1.5 Colombia Anti Obesity Drugs Market Status (2013-2017)
8.2 Latin America Anti Obesity Drugs Market Status by Manufacturers
8.3 Latin America Anti Obesity Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Anti Obesity Drugs Sales by Type (2013-2017)
8.3.2 Latin America Anti Obesity Drugs Revenue by Type (2013-2017)
8.4 Latin America Anti Obesity Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Anti Obesity Drugs Market Status by Countries
9.1.1 Middle East and Africa Anti Obesity Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Anti Obesity Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Anti Obesity Drugs Market Status (2013-2017)
9.1.4 Africa Anti Obesity Drugs Market Status (2013-2017)
9.2 Middle East and Africa Anti Obesity Drugs Market Status by Manufacturers
9.3 Middle East and Africa Anti Obesity Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Anti Obesity Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Anti Obesity Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Anti Obesity Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF ANTI OBESITY DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Anti Obesity Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 ANTI OBESITY DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Anti Obesity Drugs by Major Manufacturers
11.2 Production Value of Anti Obesity Drugs by Major Manufacturers
11.3 Basic Information of Anti Obesity Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Anti Obesity Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Anti Obesity Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 ANTI OBESITY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Pfizer
12.1.1 Company profile
12.1.2 Representative Anti Obesity Drugs Product
12.1.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Pfizer
12.2 Merck
12.2.1 Company profile
12.2.2 Representative Anti Obesity Drugs Product
12.2.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Merck
12.3 Roche
12.3.1 Company profile
12.3.2 Representative Anti Obesity Drugs Product
12.3.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Roche
12.4 GlaxoSmithKline
12.4.1 Company profile
12.4.2 Representative Anti Obesity Drugs Product
12.4.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.5 AstraZeneca
12.5.1 Company profile
12.5.2 Representative Anti Obesity Drugs Product
12.5.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
12.6 Boehringer Ingelheim
12.6.1 Company profile
12.6.2 Representative Anti Obesity Drugs Product
12.6.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
12.7 Novo Nordisk
12.7.1 Company profile
12.7.2 Representative Anti Obesity Drugs Product
12.7.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.8 Eisai
12.8.1 Company profile
12.8.2 Representative Anti Obesity Drugs Product
12.8.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Eisai
12.9 Norgine
12.9.1 Company profile
12.9.2 Representative Anti Obesity Drugs Product
12.9.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Norgine
12.10 Arena Pharmaceuticals
12.10.1 Company profile
12.10.2 Representative Anti Obesity Drugs Product
12.10.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
12.11 Orexigen Therapeutics
12.11.1 Company profile
12.11.2 Representative Anti Obesity Drugs Product
12.11.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
12.12 Vivus
12.12.1 Company profile
12.12.2 Representative Anti Obesity Drugs Product
12.12.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Vivus
12.13 Alizyme
12.13.1 Company profile
12.13.2 Representative Anti Obesity Drugs Product
12.13.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Alizyme
12.14 Rhythm Pharmaceuticals
12.14.1 Company profile
12.14.2 Representative Anti Obesity Drugs Product
12.14.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Rhythm Pharmaceuticals
12.15 Shionogi
12.15.1 Company profile
12.15.2 Representative Anti Obesity Drugs Product
12.15.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Shionogi
12.16 Zafgan
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI OBESITY DRUGS
13.1 Industry Chain of Anti Obesity Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF ANTI OBESITY DRUGS
14.1 Cost Structure Analysis of Anti Obesity Drugs
14.2 Raw Materials Cost Analysis of Anti Obesity Drugs
14.3 Labor Cost Analysis of Anti Obesity Drugs
14.4 Manufacturing Expenses Analysis of Anti Obesity Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
1.1 Definition of Anti Obesity Drugs in This Report
1.2 Commercial Types of Anti Obesity Drugs
1.2.1 Oral Medicine
1.2.2 Diet Patch
1.2.3 Diet Tea
1.3 Downstream Application of Anti Obesity Drugs
1.3.1 Men
1.3.2 Women
1.4 Development History of Anti Obesity Drugs
1.5 Market Status and Trend of Anti Obesity Drugs 2013-2023
1.5.1 Global Anti Obesity Drugs Market Status and Trend 2013-2023
1.5.2 Regional Anti Obesity Drugs Market Status and Trend 2013-2023
CHAPTER 2 GLOBAL MARKET STATUS AND FORECAST BY REGIONS
2.1 Market Development of Anti Obesity Drugs 2013-2017
2.2 Sales Market of Anti Obesity Drugs by Regions
2.2.1 Sales Volume of Anti Obesity Drugs by Regions
2.2.2 Sales Value of Anti Obesity Drugs by Regions
2.3 Production Market of Anti Obesity Drugs by Regions
2.4 Global Market Forecast of Anti Obesity Drugs 2018-2023
2.4.1 Global Market Forecast of Anti Obesity Drugs 2018-2023
2.4.2 Market Forecast of Anti Obesity Drugs by Regions 2018-2023
CHAPTER 3 GLOBAL MARKET STATUS AND FORECAST BY TYPES
3.1 Sales Volume of Anti Obesity Drugs by Types
3.2 Sales Value of Anti Obesity Drugs by Types
3.3 Market Forecast of Anti Obesity Drugs by Types
CHAPTER 4 GLOBAL MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY
4.1 Global Sales Volume of Anti Obesity Drugs by Downstream Industry
4.2 Global Market Forecast of Anti Obesity Drugs by Downstream Industry
CHAPTER 5 NORTH AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
5.1 North America Anti Obesity Drugs Market Status by Countries
5.1.1 North America Anti Obesity Drugs Sales by Countries (2013-2017)
5.1.2 North America Anti Obesity Drugs Revenue by Countries (2013-2017)
5.1.3 United States Anti Obesity Drugs Market Status (2013-2017)
5.1.4 Canada Anti Obesity Drugs Market Status (2013-2017)
5.1.5 Mexico Anti Obesity Drugs Market Status (2013-2017)
5.2 North America Anti Obesity Drugs Market Status by Manufacturers
5.3 North America Anti Obesity Drugs Market Status by Type (2013-2017)
5.3.1 North America Anti Obesity Drugs Sales by Type (2013-2017)
5.3.2 North America Anti Obesity Drugs Revenue by Type (2013-2017)
5.4 North America Anti Obesity Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 6 EUROPE MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
6.1 Europe Anti Obesity Drugs Market Status by Countries
6.1.1 Europe Anti Obesity Drugs Sales by Countries (2013-2017)
6.1.2 Europe Anti Obesity Drugs Revenue by Countries (2013-2017)
6.1.3 Germany Anti Obesity Drugs Market Status (2013-2017)
6.1.4 UK Anti Obesity Drugs Market Status (2013-2017)
6.1.5 France Anti Obesity Drugs Market Status (2013-2017)
6.1.6 Italy Anti Obesity Drugs Market Status (2013-2017)
6.1.7 Russia Anti Obesity Drugs Market Status (2013-2017)
6.1.8 Spain Anti Obesity Drugs Market Status (2013-2017)
6.1.9 Benelux Anti Obesity Drugs Market Status (2013-2017)
6.2 Europe Anti Obesity Drugs Market Status by Manufacturers
6.3 Europe Anti Obesity Drugs Market Status by Type (2013-2017)
6.3.1 Europe Anti Obesity Drugs Sales by Type (2013-2017)
6.3.2 Europe Anti Obesity Drugs Revenue by Type (2013-2017)
6.4 Europe Anti Obesity Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 7 ASIA PACIFIC MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
7.1 Asia Pacific Anti Obesity Drugs Market Status by Countries
7.1.1 Asia Pacific Anti Obesity Drugs Sales by Countries (2013-2017)
7.1.2 Asia Pacific Anti Obesity Drugs Revenue by Countries (2013-2017)
7.1.3 China Anti Obesity Drugs Market Status (2013-2017)
7.1.4 Japan Anti Obesity Drugs Market Status (2013-2017)
7.1.5 India Anti Obesity Drugs Market Status (2013-2017)
7.1.6 Southeast Asia Anti Obesity Drugs Market Status (2013-2017)
7.1.7 Australia Anti Obesity Drugs Market Status (2013-2017)
7.2 Asia Pacific Anti Obesity Drugs Market Status by Manufacturers
7.3 Asia Pacific Anti Obesity Drugs Market Status by Type (2013-2017)
7.3.1 Asia Pacific Anti Obesity Drugs Sales by Type (2013-2017)
7.3.2 Asia Pacific Anti Obesity Drugs Revenue by Type (2013-2017)
7.4 Asia Pacific Anti Obesity Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 8 LATIN AMERICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
8.1 Latin America Anti Obesity Drugs Market Status by Countries
8.1.1 Latin America Anti Obesity Drugs Sales by Countries (2013-2017)
8.1.2 Latin America Anti Obesity Drugs Revenue by Countries (2013-2017)
8.1.3 Brazil Anti Obesity Drugs Market Status (2013-2017)
8.1.4 Argentina Anti Obesity Drugs Market Status (2013-2017)
8.1.5 Colombia Anti Obesity Drugs Market Status (2013-2017)
8.2 Latin America Anti Obesity Drugs Market Status by Manufacturers
8.3 Latin America Anti Obesity Drugs Market Status by Type (2013-2017)
8.3.1 Latin America Anti Obesity Drugs Sales by Type (2013-2017)
8.3.2 Latin America Anti Obesity Drugs Revenue by Type (2013-2017)
8.4 Latin America Anti Obesity Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 9 MIDDLE EAST AND AFRICA MARKET STATUS BY COUNTRIES, TYPE, MANUFACTURERS AND DOWNSTREAM INDUSTRY
9.1 Middle East and Africa Anti Obesity Drugs Market Status by Countries
9.1.1 Middle East and Africa Anti Obesity Drugs Sales by Countries (2013-2017)
9.1.2 Middle East and Africa Anti Obesity Drugs Revenue by Countries (2013-2017)
9.1.3 Middle East Anti Obesity Drugs Market Status (2013-2017)
9.1.4 Africa Anti Obesity Drugs Market Status (2013-2017)
9.2 Middle East and Africa Anti Obesity Drugs Market Status by Manufacturers
9.3 Middle East and Africa Anti Obesity Drugs Market Status by Type (2013-2017)
9.3.1 Middle East and Africa Anti Obesity Drugs Sales by Type (2013-2017)
9.3.2 Middle East and Africa Anti Obesity Drugs Revenue by Type (2013-2017)
9.4 Middle East and Africa Anti Obesity Drugs Market Status by Downstream Industry (2013-2017)
CHAPTER 10 MARKET DRIVING FACTOR ANALYSIS OF ANTI OBESITY DRUGS
10.1 Global Economy Situation and Trend Overview
10.2 Anti Obesity Drugs Downstream Industry Situation and Trend Overview
CHAPTER 11 ANTI OBESITY DRUGS MARKET COMPETITION STATUS BY MAJOR MANUFACTURERS
11.1 Production Volume of Anti Obesity Drugs by Major Manufacturers
11.2 Production Value of Anti Obesity Drugs by Major Manufacturers
11.3 Basic Information of Anti Obesity Drugs by Major Manufacturers
11.3.1 Headquarters Location and Established Time of Anti Obesity Drugs Major Manufacturer
11.3.2 Employees and Revenue Level of Anti Obesity Drugs Major Manufacturer
11.4 Market Competition News and Trend
11.4.1 Merger, Consolidation or Acquisition News
11.4.2 Investment or Disinvestment News
11.4.3 New Product Development and Launch
CHAPTER 12 ANTI OBESITY DRUGS MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA
12.1 Pfizer
12.1.1 Company profile
12.1.2 Representative Anti Obesity Drugs Product
12.1.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Pfizer
12.2 Merck
12.2.1 Company profile
12.2.2 Representative Anti Obesity Drugs Product
12.2.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Merck
12.3 Roche
12.3.1 Company profile
12.3.2 Representative Anti Obesity Drugs Product
12.3.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Roche
12.4 GlaxoSmithKline
12.4.1 Company profile
12.4.2 Representative Anti Obesity Drugs Product
12.4.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of GlaxoSmithKline
12.5 AstraZeneca
12.5.1 Company profile
12.5.2 Representative Anti Obesity Drugs Product
12.5.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of AstraZeneca
12.6 Boehringer Ingelheim
12.6.1 Company profile
12.6.2 Representative Anti Obesity Drugs Product
12.6.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim
12.7 Novo Nordisk
12.7.1 Company profile
12.7.2 Representative Anti Obesity Drugs Product
12.7.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Novo Nordisk
12.8 Eisai
12.8.1 Company profile
12.8.2 Representative Anti Obesity Drugs Product
12.8.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Eisai
12.9 Norgine
12.9.1 Company profile
12.9.2 Representative Anti Obesity Drugs Product
12.9.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Norgine
12.10 Arena Pharmaceuticals
12.10.1 Company profile
12.10.2 Representative Anti Obesity Drugs Product
12.10.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Arena Pharmaceuticals
12.11 Orexigen Therapeutics
12.11.1 Company profile
12.11.2 Representative Anti Obesity Drugs Product
12.11.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Orexigen Therapeutics
12.12 Vivus
12.12.1 Company profile
12.12.2 Representative Anti Obesity Drugs Product
12.12.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Vivus
12.13 Alizyme
12.13.1 Company profile
12.13.2 Representative Anti Obesity Drugs Product
12.13.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Alizyme
12.14 Rhythm Pharmaceuticals
12.14.1 Company profile
12.14.2 Representative Anti Obesity Drugs Product
12.14.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Rhythm Pharmaceuticals
12.15 Shionogi
12.15.1 Company profile
12.15.2 Representative Anti Obesity Drugs Product
12.15.3 Anti Obesity Drugs Sales, Revenue, Price and Gross Margin of Shionogi
12.16 Zafgan
CHAPTER 13 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF ANTI OBESITY DRUGS
13.1 Industry Chain of Anti Obesity Drugs
13.2 Upstream Market and Representative Companies Analysis
13.3 Downstream Market and Representative Companies Analysis
CHAPTER 14 COST AND GROSS MARGIN ANALYSIS OF ANTI OBESITY DRUGS
14.1 Cost Structure Analysis of Anti Obesity Drugs
14.2 Raw Materials Cost Analysis of Anti Obesity Drugs
14.3 Labor Cost Analysis of Anti Obesity Drugs
14.4 Manufacturing Expenses Analysis of Anti Obesity Drugs
CHAPTER 15 REPORT CONCLUSION
CHAPTER 16 RESEARCH METHODOLOGY AND REFERENCE
16.1 Methodology/Research Approach
16.1.1 Research Programs/Design
16.1.2 Market Size Estimation
16.1.3 Market Breakdown and Data Triangulation
16.2 Data Source
16.2.1 Secondary Sources
16.2.2 Primary Sources
16.3 Reference
